ReNeuron receives UK regulatory approvals for Phase II clinical trial in stroke and Phase I clinical trial in critical limb ischaemia
Guildford, UK, 27 March 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L), a leading UK-based stem cell therapy company, is pleased to announce that it has received final UK regulatory and ethical approvals to commence two new clinical trials.
The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: